Clinical Psychopharmacology · Paper A
Clozapine safety
Clozapine is uniquely effective in treatment-resistant schizophreniaA long-term mental illness involving episodes of psychosis such as hallucinations and delusions.Read more → (illness that hasn't responded to other antipsychotics), but that effectiveness comes with mandatory lifelong safety monitoring. A patient on clozapine who develops a sore throat and fever is treated as a medical emergency, not a routine cold. Clozapine prescribing is inseparable from a monitoring programme, not just a medication choice.
Agranulocytosis (a dangerous fall in neutrophils, the white blood cells that fight infection) affects about 0.8% of patients, so a febrile sore throat demands an urgent neutrophil count, and a 'red' result means stopping clozapine immediately and never restarting it. Other risks include myocarditis (inflammation of the heart muscle, especially in the first weeks, checked with troponin, CRPC-reactive protein, a blood marker that rises with inflammation or infection.Read more → and ECGElectrocardiogram, a recording of the heart's electrical activity.Read more →), dose-related seizures, constipation or bowel blockage (which can be fatal), excess saliva, and metabolic syndrome (weight gain, high blood sugar and cholesterol). Smoking induces the liver enzyme CYP1A2 that breaks clozapine down, so stopping smoking raises clozapine levels: e.g. a patient on stable clozapine who stops smoking after admission to a smoke-free ward can see levels rise sharply within days, even though the dose hasn't changed. Clinically, every hospital admission is a trigger to review clozapine levels if smoking status changes.
A fresh doctor might expect all antipsychotics to share the same monitoring routine. Clozapine does not: it is reserved for treatment-resistant (illness that has not responded to at least two other antipsychotics) precisely because its benefit is unusually large, but that benefit comes bundled with monitoring requirements no other antipsychotic carries. Hold the phrase MANDATORY MONITORING through every section below.
Clozapine is an atypical antipsychotic used specifically for treatment-resistant . It requires registration with a clozapine monitoring service and regular full blood count (FBC, a blood test counting red cells, white cells, and platelets) testing for the life of the prescription, because it carries a risk of agranulocytosis (a dangerous, sudden fall in neutrophils, the white blood cells that fight infection) that no routine clinical assessment alone can detect early enough.
A common mistake is assuming a stable clozapine dose stays safe regardless of a patient's smoking status. Smoking induces the liver enzyme CYP1A2, which breaks clozapine down faster, so smokers often need higher doses. If a patient stops smoking (for example, because a hospital ward is smoke-free) that is lost, and clozapine levels can rise sharply within days on an unchanged dose, risking toxicity including sedation, hypotension, and seizures.
Imagine two patients on clozapine who both develop a sore throat and fever. One is treated as a simple viral illness and sent home; the other has an urgent checked the same day. Agranulocytosis affects around 0.8% of patients and has no reliable warning symptom other than infection: a sore throat, fever, or mouth ulcers. Because the neutrophil count can fall silently before symptoms appear, monitoring is scheduled (weekly initially, then fortnightly, then monthly once stable) rather than triggered only by how a patient feels.
A neutrophil result is graded green (continue), amber (recheck more frequently), or red (stop clozapine immediately). Once a patient has had a red result, clozapine cannot be restarted: this is one of the few genuinely irreversible prescribing decisions in psychiatry, which is why the threshold for an urgent (any fever or sore throat, not just a scheduled monitoring date) is kept deliberately low.
Myocarditis (inflammation of the heart muscle) is a serious risk especially in the first six to eight weeks of treatment, screened for with troponin, , and if a patient develops chest pain, breathlessness, or unexplained fever early in treatment. Constipation is extremely common because of clozapine's strong effect, and can progress to bowel obstruction or ileus (a paralysed, non-functioning bowel): a leading cause of clozapine-related death, which is why regular bowel-habit review and laxative use are part of routine management, not an afterthought. Dose-related seizures, hypersalivation (excess saliva, often worst at night), and metabolic syndrome (weight gain, raised blood sugar, and raised cholesterol) round out the major adverse effect profile.
A benign early fever from a viral illness should not be assumed safe without an , since agranulocytosis cannot be distinguished from a simple cold by symptoms alone. Ordinary constipation from other antipsychotics is usually milder and less likely to progress to ileus than clozapine-induced constipation, which needs proactive laxative management. Chest pain or breathlessness in the first weeks of clozapine should raise suspicion of myocarditis rather than being assumed to be anxiety or unrelated illness.
Agranulocytosis is diagnosed on the scheduled or urgent itself: a neutrophil count falling into the red range confirms it, which is why any fever or sore throat, not only the scheduled monitoring date, triggers an immediate blood draw. Myocarditis is diagnosed on a combination of troponin (a blood marker of heart muscle damage), (a marker of inflammation), and changes, prompted by chest pain, breathlessness, or unexplained fever in the first six to eight weeks; an echocardiogram may follow if these are abnormal. Clozapine-induced ileus is diagnosed clinically (reduced or absent bowel sounds, abdominal distension, and no bowel movement) supported by an abdominal X-ray or CT when bowel obstruction is suspected, and it is actively looked for, not waited on, because by the time it is obvious it can already be life-threatening.
Diagnosis and monitoring follow the clozapine monitoring service protocol (mandated by the manufacturer and reflected in BNF and Maudsley Prescribing Guidelines advice), combining scheduled screening with a low threshold for urgent testing. A red FBC result means clozapine is stopped permanently. Restarting clozapine after a treatment break of more than 48 hours requires re-titration from a low dose, since to sedation and hypotension is lost quickly. Management of constipation, hypersalivation, and metabolic risk is proactive and ongoing (regular laxatives, monitoring of weight and lipids, and dose review whenever smoking status changes) rather than reactive.
Vignettes often describe a clozapine patient with a sore throat and fever, expecting the answer to be an urgent rather than reassurance or a simple antibiotic prescription. Another common trap describes a patient who has recently stopped smoking on an unchanged clozapine dose developing sedation or a seizure: the expected recognition is a rise in clozapine level from lost CYP1A2 induction, not a new unrelated diagnosis.
Clozapine's benefit in treatment-resistant comes with mandatory monitoring for agranulocytosis, real risks of myocarditis and fatal ileus, and levels that rise sharply if a patient stops smoking, so a febrile sore throat is always an emergency FBC and a red result always ends that patient's clozapine for good.